BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency (EMA) to expand the label for VELCADE® (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). MCL is a rare and aggressive blood cancer that usually occurs in older adults.1 VELCADE, in combination with other agents, is currently licensed to treat patients with Multiple Myeloma who have not yet had therapy or whose cancer has begun to progress after treatment.2
Help employers find you! Check out all the jobs and post your resume.
